英文药名：LipaCreon（Pancrelipase Capsule/Granules） 中文药名：胰脂肪酶胶囊和颗粒 日文药名：リパクレオンカプセル/リパクレオン顆粒 生产厂家：Mylan公司EPD和雅培 治疗类别名称 膵消酵素补充 批准日期：2011年8月 欧文商標名 LipaCreon Capsule 150mg LipaCreon Granules 300mg 一般名：パンクレリパーゼ Pancrelipase（JAN） 性状 淡褐色粉末，有轻微异味。组合物的一部分是几乎不溶于水。 操作注意事项 由于这种药物是酶的活性降低是由于吸湿，颗粒剂，直到刚服用铝填料，该胶囊不从PTP板中取出之前。 适应症 在胰腺外分泌功能不全的膵消酶补充 用法与用量 口服：每日三次，每次600毫克，饭后服。此外，根据患者的病情，适当调整。 包装规格 颗粒袋装 300mg：120包，600包 胶囊 150mg：PTP：120胶囊（12粒×10），600胶囊（12粒×50） 制药公司： Mylan公司EPD 雅培日本有限公司 On August 30, we announced that we will release a pancreatic digestive enzyme replacement agent "Ripacureon capsule 150 mg" and "Ripakuleon granule 300 mg package" (generic name: punkre lipase). At the announcement this time, the company commented as follows. "In Japan," Ripacureon "was approved for manufacture and marketing by Abbott Japan with the efficacy and effect of replenishment of pancreatic exocrine enzyme in pancreatic exocrine secretory dysfunction on April 22 this year and was listed on the drug price on July 19 It was. This product is sold by Eisai Co., Ltd. and will provide medical information on proper use. This drug is the first drug used in pancreatic enzyme replacement therapy against pancreatic exocrine insufficiency (PEI: Pancreatic Exocrine Insufficiency) associated with chronic pancreatitis in the decompensated period, pancreatectomy, pancreatic cyst fibrosis etc. It contains high titers of amylase, lipase and protease extracted and purified from porcine pancreas. It is about 8 times as much as lipase per unit weight, about 7 times with protease and about 7 times as amylase It contains about 6 times the potency. In addition, it is enteric coated to prevent inactivation in the stomach, and it is designed to have an optimal particle size to be discharged into the duodenum, it can efficiently be used for digestion of patients with exocrine pancreatic insufficiency, It is expected to promote absorption and improve nutritional status. In a placebo-controlled double-blind comparative study conducted in Japan, a patient with exocrine pancreatic exocrine insufficiency due to chronic pancreatitis or pancreatectomy during decompensation period, this drug is one of the indicators of nutritional status, fat absorption We improved the rate significantly. In addition, a significant improvement in the nutritional evaluation items was observed in the long-term administration test. Main side effects reported have been constipation, diarrhea, fever, abdominal distension, hyperglycemia etc, but good tolerability was confirmed. In Europe and the United States, enzyme replacement therapy with high titer pancreatin preparation is considered as a basic treatment method for patients with exocrine pancreatic insufficiency, and this drug has already been administered in more than 80 countries including Germany, the United Kingdom and the United States It is sold under the product name "Creon" or "Kreon". Both companies will contribute to the improvement of QOL of patients by providing "Ripacureon" as a new therapeutic agent for pancreatic exocrine secretory dysfunction.